Malika Sharma, Darrell H. S. Tan
Abstract
Open-access reader
Currently, PrEP refers to prophylactic daily oral use of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), a formulation that is indicated in Canada for the treatment of HIV infection. Although licensed only in the United States for PrEP, this formulation is used off label in Canada for
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Currently, PrEP refers to prophylactic daily oral use of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), a formulation that is indicated in Canada for the treatment of HIV infection. Although licensed only in the United States for PrEP, this formulation is used off label in Canada for
Key concepts: Emtricitabine, Pre-exposure prophylaxis, Tenofovir, Human immunodeficiency virus (HIV), Medicine, Virology, Antiretroviral therapy, Men who have sex with men